Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review
Hepatitis C virus clearance is expected in more than 95% of patients treated with direct-acting antivirals (DAAs). However, an extensive debate about the impact of DAAs on the development of hepatocellular carcinoma (HCC) is currently ongoing. This review aimed to explore currently available evidenc...
Main Authors: | Mohamed El Kassas, Tamer Elbaz, Mohamed Salaheldin, Lobna Abdelsalam, Ahmed Kaseb, Gamal Esmat |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-05-01
|
Series: | Journal of Advanced Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123219300669 |
Similar Items
-
New era for management of chronic hepatitis C virus using direct antiviral agents: A review
by: Tamer Elbaz, et al.
Published: (2015-05-01) -
Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves
by: El Kassas M, et al.
Published: (2019-11-01) -
Hepatic and Intestinal Schistosomiasis: Review
by: Tamer Elbaz, et al.
Published: (2013-09-01) -
Impact of dual hepatitis B and C infection on disease severity and treatment outcome: updated review
by: Gamal Esmat, et al.
Published: (2016-01-01) -
Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)